Progress in Understanding the Role of Probiotics and Fecal Microbiota Transplantation in Regulating Inflammatory Bowel Disease

被引：0
|
作者：
Tian Y. [1 ]
Zhang C. [1 ]
Yang T. [1 ]
Dai X. [1 ]
Liu W. [1 ]
Man C. [1 ]
Zhang W. [1 ]
Jiang Y. [1 ]
机构：
[1] Key Laboratory of Dairy Science, Ministry of Education, School of Food Science, Northeast Agricultural University, Harbin
来源：
Jiang, Yujun (yujun_jiang@163.com) | 1600年 / Chinese Chamber of Commerce卷 / 42期
关键词：
Crohn's disease; Fecal microbiota transplantation; Gut microbiota; Inflammatory bowel diseases; Intestinal barrier; Probiotics; Ulcerative colitis;
D O I：
10.7506/spkx1002-6630-20200914-166
中图分类号：
学科分类号：
摘要：
Inflammatory bowel disease (IBD) is a chronic and recurrent gastrointestinal inflammatory disease, whose incidence is increasing worldwide in recent years. Its pathogenesis is complicated, which is mainly caused by the interaction of genetic, environmental and immune factors. Intensive studies of the host-gut microbial interaction have demonstrated that the intestinal microflora plays an important role in the development of IBD. Therefore, there is tremendous interest in developing new methods to relieve and treat IBD by regulating the gut microbiota. In recent years, a large number of studies have proved that probiotics and fecal microbiota transplantation (FMT) may alleviate IBD by regulating the composition of intestinal microflora, enhancing the mucosal barrier function and regulating the immune response. This article reviews the recent progress in the pathogenesis of IBD and the application of probiotics and fecal bacteria transplantation on IBD. © 2021, China Food Publishing Company. All right reserved.
引用
收藏
页码：250 / 259
页数：9
相关论文
共 104 条
  • [1] LANIS J M, KAO D J, ALEXEEV E E, Et al., Tissue metabolism and the inflammatory bowel diseases, Journal of Molecular Medicine, 95, 9, pp. 905-913, (2017)
  • [2] CARUSO R, LO B C, NUNEZ G., Host-microbiota interactions in inflammatory bowel disease, Nature Reviews Immunology, 20, 7, pp. 411-426, (2020)
  • [3] CARUSO R, MATHES T, MARTENS E C, Et al., A specific genemicrobe interaction drives the development of Crohn's disease-like colitis in mice, Science Immunology, 4, 34, (2019)
  • [4] KAPLAN G G., The global burden of IBD: from 2015 to 2025, Nature Reviews Gastroenterology & Hepatology, 12, 12, pp. 720-727, (2015)
  • [5] CHI K R., Epidemiology: rising in the East[J], Nature, 540, pp. S100-S102, (2016)
  • [6] OKA A, SARTOR R B., Microbial-based and microbial-targeted therapies for inflammatory bowel diseases, Digestive Diseases and Sciences, 65, 3, pp. 757-788, (2020)
  • [7] SAIRENJI T, COLLINS K L, EVANS D V., An update on inflammatory bowel disease, Primary Care, 44, 4, pp. 673-692, (2017)
  • [8] XAVIER R J, PODOLSKY D K., Unravelling the pathogenesis of inflammatory bowel disease, Nature, 448, pp. 427-434, (2007)
  • [9] 4
  • [10] HAMPE J, CUTHBERT A, CROUCHER P J, Et al., Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations, The Lancet, 357, pp. 1925-1928, (2001)
12345678910